Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,082.01 +11.46 (+0.23%) Dow
38,497.60 -6.09 (-0.02%) Nasdaq
15,801.89 +105.25 (+0.67%) Bitcoin USD
66,124.95 -425.74 (-0.64%) CMC Crypto 200
1,427.50 +3.40 (+0.24%)
Kazia Therapeutics Limited (KZIA)
| Previous close | 0.3950 |
| Open | 0.3817 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.3734 - 0.3898 |
| 52-week range | 0.1900 - 1.4100 |
| Volume | |
| Avg. volume | 896,369 |
| Market cap | 9.843M |
| Beta (5Y monthly) | 2.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7200 |
| Earnings date | 27 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.98 |
Insider Monkey11 Best ASX Stocks To Buy Now
In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy Now. With a market capitalization of $1.5 trillion, the Australian stock exchange, […]
PR NewswireKazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company specializing in central nervous system (CNS) diseases, to develop, manufacture and commercialise paxalisib as a potential treatment of intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease. The underlying cause of FCD T2 a
- PR Newswire
Kazia announces presentation of new data at AACR Annual Meeting
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.
